Results 61 to 70 of about 39,176 (275)

The time has come for revising the rules of clozapine blood monitoring in Europe. A joint expert statement from the European Clozapine Task Force

European Psychiatry
The European Clozapine Task Force is a group of psychiatrists and pharmacologists practicing in 18 countries under European Medicines Agency (EMA) regulation, who are deeply concerned about the underuse of clozapine in European countries.
Hélène Verdoux, Robert A. Bittner, Alkomiet Hasan, Mishal Qubad, Elias Wagner, Alexis Lepetit, Manuel Arrojo-Romero, Christian Bachmann, Marieke Beex-Oosterhuis, Jan Bogers, Andreja Celofiga, Dan Cohen, Domenico de Berardis, Marc de Hert, Carlos de Las Cuevas, Bjørn H. Ebdrup, Konstantinos N. Fountoulakis, Daniel Guinart, Dolores Keating, Miloslav Kopeček, John Lally, Judit Lazáry, Jurjen J. Luykx, Olalla Maronas Amigo, Espen Molden, Jimmi Nielsen, Brian O’Donoghue, Pierre Oswald, Flavian S. Radulescu, Christopher Rohde, Marina Sagud, Emilio J. Sanz, Ivona Šimunović Filipčić, Iris E. Sommer, Heidi Taipale, Jari Tiihonen, Heli Tuppurainen, Selene Veerman, Alina Wilkowska, Edoardo Spina, Peter Schulte   +40 more
doaj   +1 more source

Delayed onset, protracted delirium and aspiration pneumonitis associated with a combination of clozapine and electroconvulsive therapy

Indian Journal of Psychological Medicine, 2011
Few studies reported the efficacy and safety in combination of clozapine and electroconvulsive therapy (ECT) in schizophrenia; systematic studies are lacking. Side effects like seizure, and confusional state are reported.
N Manjunatha, G S Ram Kumar, R Vidyendaran, K Muralidharan, J P John   +4 more
doaj   +1 more source

Treatment-resistant schizophrenia : the relationship between clozapine plasma concentration and clinical outcome

European Psychiatry, 2022
Introduction Clozapine is highly effective in patients with treatment-resistant schizophrenia but, to ensure optimal clinical response it is important to optimize its use and this depends on adequate pharmacological monitoring.
I. Kammoun, R. Jouini, A. Aissa, R. Boukhchina, Y. Zgueb, E. Khelifa, U. Ouali, R. Jomli, F. Nacef, Z. El Hechmi   +9 more
doaj   +1 more source

The Effect of Clozapine on Tremor in Patients with Parkinson’s Disease who were Initiated Clozapine For Psychotic Symptoms

, 2013
Aim: Tremor is one of the initial symptoms of Parkinson’s disease and most of the patients suffer from it along the course of the disease. Levodopa and dopamine agonists are used as first-line therapy.
Aytül Mutlu, Hasan Meral, Belgin Petek Balcı, Feriha Özer, Özlem Çokar, Emel Oğuz Akarsu, Mithat Bedir   +6 more
core   +1 more source

Barriers to using clozapine in treatment-resistant schizophrenia: systematic review [PDF]

, 2019
Aims and methodTo systematically review the literature on barriers to the use of clozapine and identify any interventions for optimizing clozapine use in treatment-resistant schizophrenia. Journal databases were searched from 1972 to March 2018.
Farooq
core   +1 more source

ACKR1/Duffy‐null genotype testing for clozapine: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI‐PGx)

British Journal of Clinical Pharmacology, EarlyView.
Abstract Clozapine is licenced for treatment‐resistant schizophrenia and psychosis in Parkinson's disease. In the United Kingdom, there is a mandatory requirement for absolute neutrophil count (ANC) and white blood cell count (WBC) monitoring to safeguard against agranulocytosis.
Stephen Murtough, Oriella Stellakis, Daisy Mills, Blanca Bjourson, Vicky Chaplin, Dharmisha Chauhan, Bev Chipp, Marius Cotic, Jana de Villiers, Olubanké Dzahini, Frances Elmslie, Katie Evans, Shreyans Gandhi, Dyfrig A. Hughes, Huajie Jin, Daniele Panconesi, Anna Skowronska, Sanjay M. Sisodiya, Ed Silva, Vicky Stinton, Sara Stuart‐Smith, Sarah Tarrant, David Taylor, Lauren Varney, James T. R. Walters, Michelle Wood, Jessica Woodley, Cinzia Dello Russo, Munir Pirmohamed, Elvira Bramon   +29 more
wiley   +1 more source

Endogenous melatonin partial metabolic clearance as a potential endogenous marker of CYP1A2 activity

British Journal of Clinical Pharmacology, EarlyView.
Aims Cytochrome P450 1A2 (CYP1A2) exhibits substantial interindividual variability, necessitating appropriate phenotyping strategies for personalized pharmacotherapy. This study evaluated endogenous melatonin partial metabolic clearance (CLm(MEL)), calculated from urinary 6‐hydroxymelatonin (6‐O‐MEL) excretion and plasma melatonin (MEL) exposure, as a ...
Akitomo Yokokawa, Hayato Shimazaki, Shunji Igarashi, Yoshiki Tagawa, Naoki Hisada, Hiromi Shibasaki   +5 more
wiley   +1 more source

Clozapine-induced transcriptional changes in the zebrafish brain

, 2020
Clozapine is an atypical antipsychotic medication that is used to treat schizophrenia patients who are resistant to other antipsychotic drugs. The molecular mechanisms mediating the effects of clozapine are not well understood and its use is often ...
G Paull (16134680), A Farbos (21831614), E Santos (9644657), J Viana (7718465), N Wildman (21914216), R Van Aerle (21914219), P O'Neill (9873590), J Mill (17767260), E Hannon (16180526), K Moore (9720572)   +9 more
core  

Mild N‑Arylation of Sulfoximines With (Hetero)aryl Chlorides Enabled by α‐Methylnaphthyl‐tBuBrettPhos Palladium Triflate

Chemistry – A European Journal, EarlyView.
A readily accessible, air‐ and moisture‐stable palladium precatalyst, [Pd(1‐MeNAP)(tBuBrettPhos)]OTf, enables the direct N‐arylation of NH‐sulfoximines with (hetero)aryl chlorides under exceptionally mild conditions ideal for late‐stage diversification of drug‐like scaffolds.
Sourav Manna, Mahima Pilania, Kumarjit Sen, Nikolaos V. Tzouras, Angelino Doppiu, Lukas J. Gooßen   +5 more
wiley   +1 more source

PharmVar GeneFocus: CYP1A2—Clinical Impact, Genetic Variation, and Updated Nomenclature

Clinical Pharmacology &Therapeutics, EarlyView.
The Pharmacogene Variation Consortium (PharmVar) provides nomenclature for the highly polymorphic human CYP1A2 gene. CYP1A2 plays a crucial role in the biotransformation of several commonly used drugs, including antipsychotics, antidepressants, anxiolytics, and methylxanthines.
Katalin Monostory, Gonzalo Villapalos Garcia, Dora Koller, Solomon Adams, Chad A. Bousman, Evangelia Eirini Tsermpini, Michelle Whirl‐Carrillo, Amy J. Turner, Volker M. Lauschke, Mohamed Nagy, Erin C. Boone, Teri E. Klein, Pablo Zubiaur, Andrea Gaedigk   +13 more
wiley   +1 more source